Label Image (Lbl500907692)
Sertraline Hydrochloride Tablet
Product Images NDC 50090-7692
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sertraline Hydrochloride (NDC 50090-7692). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image Description (Struct)
Table 3 (Table 3)
This text provides a table detailing the common adverse reactions reported in pooled placebo-controlled trials with adults suffering from various conditions like MDD, OCD, and PTSD, among others, and treated with Sertraline Hydrochloride compared to Placebo. The adverse reactions include symptoms like palpitations, visual impairment, gastrointestinal issues, fatigue, decreased appetite, dizziness, somnolence, insomnia, agitation, and sexual dysfunction, among others. The table also highlights the percentage of occurrence for each adverse reaction.*
Table1 (Table1)
This text provides information about the recommended daily dosage of sertraline hydrochloride for adult patients with MDD, OCD, PD, PTSD, and SAD. It includes starting doses and therapeutic ranges for each condition. Additionally, dosages for pediatric patients with OCD aged 6-12 years old and 13-17 years old are also mentioned.*
Table2 (Table2)
This text provides a table detailing the Risk Differences in the number of cases of suicidal thoughts or behaviors in placebo-controlled trials of antidepressants in pediatric and adult patients. It shows the Age Range, Drug-Placebo Difference in Number of Patients of Suicidal Thoughts or Behaviors per 1000 Patients Treated, and the Increase or Decrease compared to Placebo for different age groups. The data reveals that there were additional patients with suicidal thoughts or behaviors in the <18 age group and 18-24 age group compared to placebo, while there were fewer patients in the older age groups.*
Image Description (Table4)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
